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1  | INTRODUC TION
The two principle diseases that dentistry must manage are dental 
caries and periodontal disease. Whilst they have different patholog‐
ical aetiologies, both are caused by bacteria and can lead ultimately 
to tooth loss. Dental caries is predominantly a disease of childhood 
and adolescence, whereas periodontal disease normally affects indi‐
viduals in middle to old age. The morbidity of these two diseases has 
recently been described as ‘a major public health problem … that af‐
fects almost everyone in their life courses’.1  Their impact can be de‐
scribed in a variety of ways: the direct cost is estimated as €79 billion 
annually in Europe,2  which is greater than the expenditure on stroke, 
cancer, respiratory disease or Alzheimer's; the indirect cost mea‐
sured in days lost (school or work) is 4.14 million days in Canada;3  
and there is the incalculable cost to the individual of anxiety, pain 
and suffering. In 2005, caries was estimated to affect 60–90% of 
1 Jin,	 L.	 J.,	 Lamster,	 I.	B.,	Greenspan,	 J.	 S.,	Pitts,	N.	B.,	 Scully,	C.,	&	Warnakulasuriya,	 S.	
(2016).	 Global	 burden	 of	 oral	 diseases:	 Emerging	 concepts,	management	 and	 interplay	
with systemic health. Oral Dis., 22, 609–619.
2 Patel,	R.	(2012).	The state of oral health in Europe.	(Report	commissioned	by	the	platform	
for	 better	 oral	 health	 in	 Europe)	 Retrieved	 from	 http://www.oralhealthplatform.eu/
wp-content/uploads/2015/09/Report-the-State-of-Oral-Health-in-Europe.pdf.	Accessed	
Oct,	2017
3 Hayes,	A.,	Azarpazhooh,	A.,	Dempster,	L.,	Ravaghi,	V.,	&	Quiñonez,	C.	(2013).	Time	loss	
due to dental problems and treatment in the Canadian population: Analysis of a nation‐
wide cross‐sectional survey. BMC Oral Health, 13, 17.
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Abstract
Our	understanding	of	the	complexity	of	the	oral	biome	and	of	the	role	of	the	various	
constituent	bacteria	in	the	aetiology	of	dental	disease	is	growing.	Probiotics	and	their	
relationship with prebiotics, as well as other microbiome‐based interventions, could 
be useful in preventing and treating dental disease and in promoting oral health. 
However,	given	the	promise	and	early	stage	of	 this	 treatment	approach,	 there	are	
also a number of ethical, social and regulatory issues associated with innovative pro‐
biotic therapy. In this article, a brief update is given on contemporary theories of the 
aetiology and management of the two commonest dental diseases, and on the roles 
of pre‐ and probiotics and oral biome transplant in the management of these dis‐
eases. The focus is primarily on four core issues: informed consent, risk–benefit as‐
sessment, how to determine suitable healthy donors, and commercialization and 
regulation. We discuss the safety and benefits of oral probiotics, not only concerning 
the products and quality control during their manufacture, but also regarding the 
depth of public knowledge about this topic. We point out that the requirement of 
listing ingredients honestly might be insufficient, and that the prevalent rhetoric of 
‘natural’ and ‘organic’ as well as some health claims in the translational, innovative 
probiotic industry and markets are themselves misleading and should be carefully 
scrutinized.	Finally,	we	suggest	an	ethical	imperative	to	find	a	balance	between	scien‐
tific research and industry, and public health in the regulation of probiotics.
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children and 100% of adults worldwide.4 	 The	 Global	 Burden	 of	
Diseases has placed dental caries first out of 261 diseases and peri‐
odontal disease sixth,5  and, amongst children, caries has a five‐fold 
higher prevalence than asthma, the second highest condition.6 
2  | AETIOLOGY OF C ARIES AND 
PERIODONTAL DISE A SE
In a healthy mouth there is a stable relationship between the biome 
and	 host	 (microbial	 homeostasis).	 The	 Human	 Oral	 Microbiome	
Database	(HOMD)	records	22	different	genera	and	688	taxa	of	bac‐
teria.7  Contemporary methods of analysis of the bacterial spectrum 
reveal a picture that varies within and between individuals, at differ‐
ent locations within the mouth, between children and adults, be‐
tween healthy individuals and those with a disease, at different 
times of day, and with different diets.8  Mira et al. state in a recent 
review article that ‘The processes which underlie the development 
and stability of microbial populations in the healthy mouth are fun‐
damental to understanding how the populations are transformed 
into a dysbiotic state in disease.’9  Zarco et al. describe a core micro‐
biome that is common to all individuals, and a variable microbiome 
that is influenced by a number of host factors such as lifestyle, physi‐
ology, immune system, environment, pathobiology and genotype.10  
The acquisition of the oral biome and its variety alters over time, and 
depends on a number of factors such as vaginal or caesarean 
delivery, breast or bottle feeding, saliva exchange, and eruption of 
teeth.	Later	in	life,	the	presence	of	orthodontic	appliances	or	pros‐
thetics will alter the biome, along with other factors (see below).
Early bacterial colonizers of the acquired pellicle of the tooth are 
mainly Streptococcus sanguinis and Actinomyces. Their metabolism 
creates an extracellular matrix that permits other bacterial species to 
adhere and protects the plaque biofilm. The mature plaque includes 
fusobacterium, which link the early colonizers with the later species. 
The exact microbial composition of plaque varies according to local 
ecological factors and position on the tooth.11 	 Plaque	may	 either	
trap and envelop a potential pathogen, reducing its virulence, or it 
may allow a pathogen to hide within, protecting it from the host de‐
fences.12 	Sanz	et	al.	note	that	as	caries	develops,	microbial	diversity	
at the site reduces, whereas with periodontal disease, there is an 
increase in microbial diversity and an ability to withstand the host's 
immune and inflammatory response.13 
Changes in the oral biome may be caused by an alteration of the 
balance between bacteria, owing to factors such as insufficient oral 
hygiene measures, changes in the nutrients available to the biome, 
salivary flow, local or systemic medication, or changes to the im‐
mune system of the host.14 
The two streptococci (Streptococcus mutans and Streptococcus 
sobrinus) most associated with caries are a small proportion of the 
plaque	colony.	Both	are	highly	acidodogenic,	and	S. sobrinus is also 
aciduric. An increase in available sucrose tips the balance towards 
these	aggressive	cariogenic	strains,	with	a	 resultant	 fall	 in	pH	and	
demineralization of the enamel surface.15  Marsh suggests that oral 
biofilms may be better characterized by their metabolic activity (aci‐
dogenic, aciduric, and acid‐tolerant) as cariogenic rather than by the 
predominant species.16 
Gingivitis	 is	caused	when	the	plaque	biofilm	around	the	supra-
gingival margin of the tooth is not disturbed and a complex mix of 
aerobic and anaerobic, gram‐positive and gram‐negative rods and 
cocci flourish in the gingival sulcus. The inflammation of the gingiva 
increases the gingival exudate, which is a rich nutrient.17 	Progression	
to periodontal disease (which takes place sub‐gingivally) is charac‐
terized by the three Cs: Community change, microbial Complexes 
and Commensal involvement, the latter suggesting that normally 
commensal bacteria may alter their role in a disease state.18 
4 Petersen,	P.	E.,	Bourgeois,	D.,	Ogawa,	H.,	Estupinan-Day,	S.,	&	Ndiaye,	C.	 (2005).	The	
global burden of oral diseases and risks to oral health. B. World Health Organ., 83, 
661–669.
5 Marcenes,	W.,	 Kassebaum,	 N.	 J.,	 Bernabé,	 E.,	 Flaxman,	 A.,	 Naghavi,	M.,	 Lopez,	 A.,	 &	
Murraym,	C.	 J.	 L.	 (2013).	Global	burden	of	oral	 conditions	 in	1990–2010:	A	systematic	
analysis. J Dent. Res., 92,	592–597;	Kassebaum,	N.	J.,	Bernabe,	E.,	Dahiya,	M.,	Bhandari,	B.,	
Murray,	C.	J.,	&	Marcenes,	W.	(2014).	Global	burden	of	severe	periodontitis	in	1990–2010:	
A systematic review and meta‐regression. J. Dent. Res., 93, 1045–1053.
6 Simón-Soro,	A.,	&	Mira,	A.	(2015).	Solving	the	etiology	of	dental	caries.	Trends Microbiol., 
23,	76-82.
7 Costalonga,	M.,	&	Herzberg,	M.	C.	(2014).	The	oral	microbiome	and	the	immunology	of	
periodontal disease and caries. Immunol. Lett., 162,	22–38.
8 Kilian,	M.,	Chapple,	 I.	L.	C.,	Hannig,	M.,	Marsh,	P.	D.,	Meuric,	V.,	Pederson,	A.	M.	L.,	…	
Zaura, E. (2016). The oral microbiome – an update for oral healthcare professionals. Brit. 
Dent. J., 221,	 657–666;	 Alcaraz,	 L.	 D.,	 Belda-Ferre,	 P.,	 Cabrera-Rubio,	 R.,	 Romero,	 H.,	
Simón-Soro,	A.,	Pignatelli,	M.,	&	Mira,	A.	 (2012).	 Identifying	a	healthy	oral	microbiome	
through metagenomics. Clin. Microbiol. Infec., 18	(Suppl.	4),	54–57;	Benn,	A.	M.	L.,	Heng,	N.	
C.	K.,	Broadbent,	J.	M.,	&	Thomson,	W.	M.	(2018).	Studying	the	human	biome:	Challenges	
and the evolution of solutions. Austral. Dent. J., 63,	14–24;	Sanz,	M.,	Beighton,	D.,	Curtis,	
M.	A.,	Cury,	J.	A.,	Dige,	I.,	Dommisch,	H.,	...	Krönönen,	E.	(2017).	Role	of	microbial	biofilms	
in the maintenance of oral health in the development of dental caries and periodontal 
diseases.	Consensus	report	of	group	1	of	the	Joint	EFP/ORCA	workshop	on	the	boundar‐
ies between caries and periodontal disease. J. Clin. Periodontol., 44	 (Suppl.	18),	S5–S11;	
Mira,	 A.,	 Simon-Soro,	 A.,	 &	 Curtis,	M.	 A.	 (2017).	 Role	 of	microbial	 communities	 in	 the	
pathogenesis of periodontal diseases and caries. J. Clin. Periodontol., 44	(Suppl.	18),	S23–
S38;	Gao,	L.,	Xu,	T.,	Huang,	G.,	Jiang,	S.,	Gu,	Y.,	&	Chen,	F.	(2018).	Oral	microbiomes:	More	
and more importance in oral cavity and whole body. Protein Cell., 9,	488–500;	Burczynska,	
A.,	Dziewit,	L.,	Decewicz,	P.,	Struzycka,	I.,	&	Wroblewska,	M.	(2017).	Application	of	metag‐
nomic analyses in dentistry as a novel strategy enabling complex insight into microbial 
diversity of the oral cavity. Polish J. Microbiol., 66, 9–15
9 Mira,	Simon-Soro,	Curtis	op. cit. note 13.
10 Zarco,	M.	F.,	Vess,	T.	J.,	&	Ginsberg,	G.	S.	(2012).	The	oral	microbiome	in	health	and	dis‐
ease and the potential impact in personalized dental medicine. Oral Diseases, 18, 
109–120.
11 Larsen,	 T.,	 &	 Fiehn,	 N.-E.	 (2017).	 Dental	 biofilm	 infections	 –	 an	 update.	APMS, 125, 
376–384.
12 Zarco,	Vess,	&	Ginsberg,	op. cit. note 17.
13 Sanz	et	al.	op. cit. note 12.
14 Larsen	&	Fiehn	op. cit.	note	18;	Marsh,	P.	D.,	&	Zaura,	E.	(2017).	Dental	biofilm:	Ecological	
interactions in health and disease. J. Clin. Periodontol., 44	(Suppl.	18),	S12–S22.
15 Kneist,	S.,	Kupper,	H.,	Raser,	G.,	Willerhausen,	B.,	&	Callaway,	A.	(2015).	Penetration	of	
Streptococcus sobrinus and Streptococcus sanguinis into dental enamel. Anaerobe, 35, 
54–59
16 Marsh,	P.	D.	(2018).	In	sickness	and	in	health	–	what	does	the	oral	microbiome	mean	to	
us? An ecological perspective. Adv. Dent. Res., 29, 60–65
17 Larsen	&	Fiehn	op. cit.	note	18.
18 Mira	et	al.	op. cit. note 13.
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More recently, attention has turned to an understanding of the role 
of host genetic markers in the susceptibility to (predominantly) peri‐
odontal disease, and caries.19  The mechanism is poorly understood at 
present, but a lack of the genes that are responsible for the production 
of particular proteins or antibodies in saliva may allow plaque to flourish. 
In a recent monograph, the American Dental Association suggested that 
the presence of candidate genes for either disease, whilst identifiable, 
does not currently have a role in their practical management.20 
Other	recognized	aetiological	factors	in	dental	disease	include	the	
occupation, education level, income, and socioeconomic status of the 
individual.21  In addition, the dietary habits of individuals in low‐socio‐
economic groups tend towards the consumption of large quantities of 
carbonated drinks with added sugar.22 	 Reduced	 health-seeking	 be‐
haviour is also linked to low socioeconomic status, fear and perceived 
discrimination.23  The squeeze on the purse of low‐income groups can 
also mean that regular purchases of toothbrushes and toothpaste may 
not be a priority. This adds to the challenge of managing dental disease 
in vulnerable groups, and makes the development of simple, non‐inva‐
sive, and financially accessible management methods that require min‐
imal cooperation an important objective.
3  | PRE VENTION OF DENTAL C ARIES
Caries is a multifactorial disease and requires ‘a holistic approach of effec‐
tive mechanical plaque control, diet modification and modulation of the 
oral microbiota’.24  A variety of measures have been employed to prevent 
dental caries at individual, professional and public health levels. Individual 
activities include mechanical disruption of the biofilm by toothbrushing, 
with the addition of toothpaste containing fluoride, where the latter in‐
creases the resistance of the enamel surface to acid attack and/or remin‐
eralizes surface enamel that has already suffered acid attack, and possibly 
has an antimicrobial effect on the biofilm. This, together with a diet that is 
low in refined sugar, is believed to be the most effective preventive meas‐
ure that the patient can undertake. More recently, the presence of argi‐
nine (a semi‐essential amino acid) or enzymes and proteins in toothpaste 
has been shown to produce a favourable shift in the salivary biome that 
leads to a reduction of sucrose conversion to lactate.25 
Much research has been devoted to the use of sugar‐free chewing 
gum.	Post-prandial	use	of	gum,	with	its	associated	increased	salivary	
flow, reduces caries attack. In addition to the non‐sugar sweetener 
(xylitol), additives to gum such as antimicrobial agents or herbal ex‐
tract,26  eucalyptus,27  calcium bicarbonate, chlorhexidine, and/or flu‐
oride28  have been shown to have a beneficial effect on caries and 
periodontal parameters. Chewing manuka honey extract has been 
found to reduce plaque scores,29  and a gum containing a probiotic 
(Lactobacilli reuteri) has reduced salivary mutans streptococci.30 
Professional	 support	 in	 the	 form	 of	 regular	 attendance	 at	 the	
dentist's office to allow early advice or interception of incipient 
problems	 is	 important.	 Support	 also	 includes	 the	 application	 of	
topical fluoride in a variety of modalities, prescription of fluoride 
supplements, the application of fissure sealants, and the use of flu‐
oride‐releasing restorative materials (such as glass ionomer cement).
The concept of manipulation of the oral biome to eliminate or 
attenuate the effects of cariogenic bacteria is attractive; however, 
our understanding of the oral biome in both healthy and caries states 
is incomplete. The complexity of the inter‐relationship between 
pathogens, non‐pathogens and potential pathogens makes the prac‐
tical aspects of manipulation challenging.31 
The adjustment of the proportion of fluoride in drinking water 
has proved to be an effective public health measure for the reduc‐
tion of caries in the population.32 	Other	public	health	measures	in‐
clude the addition of fluoride to foodstuffs such as milk or salt.33 
The use of a vaccine against caries has been reported since the 
late 1960s. A number of antigens are in development targeted at 
Streptococcus mutans.34  This is still at an experimental stage, with 
some success being evident in murine models. The development of a 
vaccine as a public health measure to be administered during the first 
year of life would be highly desirable, but seems remote at present.
19 Kornman,	K.	S.,	&	Polverini,	P.	J.	(2014).	Clinical	application	of	genetics	to	guide	preven‐
tion and treatment of oral diseases. Clin. Genet., 86,	44–49;	Nibali,	L.,	Dilorio,	A.,	Tu,	Y.-K.,	
&	Vieira,	A.	R.	(2017).	Host	genetics	role	in	the	pathogenesis	of	periodontal	disease	and	
caries. J. Clin. Periodontol., 44	(Suppl.	18),	S52–S78
20 Genetic	 Testing	 Workgroup.	 ADA	 Council	 on	 Scientific	 Affairs.	 Genetics	 and	 Oral	
Health.	(2017).	Retrieved	from	https://www.ada.org/en/member-center/oral-health-top‐
ics/genetics-and-oral-health.	Accessed	Aug,	2018.
21 Costa,	S.	M.,	Martins,	C.	C.,	Bonfilm,	M.	de	L.	C.,	Zina,	L.	G.,	Paira,	S.	M.,	Pordeus,	I.	A.,	&	
Abreu,	M.	H.	N.	G.	 (2012).	A	systematic	review	of	socioeconomic	 indicators	and	dental	
caries in adults. Int. J. Environ. Res. Pub. Health, 9, 3540–3574.
22 Hamasha,	A.	A.-H.,	Warren,	J.	J.,	Broffitt,	B.,	&	Kanellis,	M.	J.	 (2006).	Oral	health	be‐
haviours of children in low and high socioeconomic status families. Paediatr. Dent., 28, 
310–315;	Hong,	J.,	Whelton,	H.,	Douglas,	G.,	&	Kang,	J.	(2018).	Consumption	frequency	of	
added sugars and UK children's dental caries. Community Dent. Oral Epidemiol., 46,	1–8.
23 Wamala,	S.,	Merlo,	J.,	&	Boström,	G.	(2006).	Inequity	in	access	to	dental	care	services	
explains	current	socioeconomic	disparities	in	oral	health:	The	Swedish	National	Survey	of	
Public	Health	 2004–2005.	 J. Epidemiol. Community Health, 60,	 1027–1033;	Wamala,	 S.,	
Merlo,	 J.,	Boström,	G.,	&	Hogstedt,	C.	 (2007).	Perceived	discrimination,	 socioeconomic	
disadvantage	 and	 refraining	 from	 seeking	 medical	 treatment	 in	 Sweden.	 J. Epidemiol. 
Community Health, 61, 409–415.
24 Marsh	op. cit. note 24.
25 Adams,	S.	E.,	Arnold,	D.,	Murphy,	B.,	Carroll,	P.,	Green,	A.	K.,	Smith,	A.	M.,	...	Brading,	M.	
G.	(2017).	A	randomized	clinical	study	to	determine	the	effect	of	a	toothpaste	containing	
enzymes and proteins on plaque microbiome ecology. Sci. Rep., 7, 43344. https://doi.
org/10.1038/srep43344
26 Keukenmeester,	R.	S.,	Slot,	D.	E.,	Putt,	M.	S.,	&	Van	der	Weijden,	G.	A.	(2014).	The	effect	
of medicated, sugar‐free chewing gum on plaque and clinical parameters of gingival in‐
flammation: A systematic review. Int. J. Dent. Hygiene, 12, 2–16.
27 Nagatu,	H.,	Inagaki,	Y.,	Tanaka,	M.,	Ojima,	M.,	Kataoka,	K.,	Kubiniwa,	M.,	...	Shizukuishi	S.	
(2008).	 Effect	 of	 eucalyptos	 extract	 chewing	 gum	 on	 periodontal	 health:	 A	 double-
masked, randomised trial. J Periodontol., 79,	1378–1385.
28 Ly,	K.	A.,	Milgrom,	P.,	&	Rothen,	M.	(2008).	The	potential	of	dental-protective	chewing	
gum in oral health interventions. JADA, 139, 553–563.
29 English,	H.	K.,	Pack,	A.	R.,	&	Molan,	P.	C.	(2004).	The	effects	of	Manuka	honey	on	plaque	
and gingivitis: A pilot study. Int. J. Acad. Periodontol., 6, 63–67.
30 Çaglar,	E.,	Kavaloglu,	S.	C.,	Kuscu,	C.	D.,	Sandalli,	N.,	Holgerson,	P.	L.,	&	Twetman,	S.	
(2007) Effect of chewing gum containing xylitol or probiotic bacteria on salivary mutans 
streptococci and lactobacilli. Clin. Oral Invest., 11, 425–429.
31 Marsh	op. cit. note 24.
32 Iheozor-Ejiofor,	Z.,	Worthington,	H.	V.,	Walsh,	T.,	O'Malley,	L.,	Clarkson,	J.	E.,	Macey,	R.,	
…	Glenny,	A.	M.	(2015).	Water	fluoridation	for	the	prevention	of	dental	caries	(Review).	
Cochrane Database of Systematic Reviews, 6,	Art.	No.:	CD010856.
33 Espelid,	I.	(2009).	Caries	preventive	effect	of	fluoride	in	milk,	salt	and	tablets:	A	litera‐
ture review. Europ. Arch. Paed. Dent., 10, 149‐156.
34 Taubman,	M.	A.,	&	Nash,	D.	A.	(2006).	The	scientific	and	public-health	imperative	for	a	
vaccine against dental caries. Nature Reviews Immunology, 6, 555–563.
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4  | PRE VENTION OF PERIODONTAL 
DISE A SE
Although current approaches to periodontal therapy have been shown 
to improve periodontal health and reduce the rate of further clinical 
attachment loss and tooth loss, they fall short of completely arresting 
the disease.35 	Gingivitis	is	a	normal	precursor	to	the	more	destructive	
periodontal	disease.	Gingivitis	may	be	controlled	or	reversed	by	effi‐
cient toothbrushing. The purchase of toothpastes with various antisep‐
tic additives, together with antiseptic mouthwashes available ‘over the 
counter’ from pharmacies, is a measure that the patient can take. 
Chlorhexidine at 0.2% concentration has been shown to be effective as 
an antiplaque agent, and, although the side‐effects of acquired brown 
stains on the teeth are well known, it has superior antiplaque properties 
to another popular mouthwash containing essential oils.36 
Progression	from	gingivitis	to	periodontal	disease	means	that	more	
intrusive and invasive procedures by the dental profession are required. 
These range from a regular scale and polish (to help control gingivitis), to 
deep scaling, periodontal surgery or the placement of antimicrobial‐
loaded ‘wicks’ into the gingival crevice.37  Whilst the above measures are 
valuable in establishing a clean mouth, compliance with adjunctive oral 
cleansing methods by the patient is a complex area,38  and individually 
tailored programmes, also known as personalized dental medicine,39  
are demanding for the individual and the professional.
A new approach to the challenge of treating periodontal disease, 
where the gram‐negative pathogens are working in an anaerobic en‐
vironment deep within the periodontal pocket or plaque deposit, 
and protected from the actions of normal oral cleansing methods, 
involves the use of a different bacteria that will kill the pathogen – a 
pathogen predator.40  In vitro experiments have shown that 
Bdellovibrio bacteriovorus	HD100	can	attack	some	key	gram-negative	
bacteria in periodontal disease, but their efficiency reduced as the 
complexity of the model increased, and there were other, non‐
pathogen,	species	that	were	also	attacked.	Loozen	et	al.	and	Marsh	
et al. suggested that some antimicrobial agents might instead inhibit 
the growth and metabolism of the disease‐causing organisms, allow‐
ing those associated with health to flourish once more.41 
There is little that can be achieved to combat periodontal disease 
within the dental public health arena other than public health awareness 
campaigns of the benefits of regular attendance at the dental office, tooth‐
brushing, and controlled use of antimicrobial mouth‐rinses or toothpaste.
For	both	caries	and	periodontal	disease,	 the	use	of	 interdental	
floss and/or small interdental brushes by the patient has been rec‐
ommended as a preventive measure. Whilst both caries and peri‐
odontal disease could be controlled by scrupulous personal oral 
hygiene and dietary discipline, socio‐behavioural attitudes militate 
against	this.	New	strategies	for	finding	successful	ways	of	treating	
the twin threats of these diseases using our growing understanding 
of the ecology of the oral biome show promise.
5  | PROBIOTIC S,  PREBIOTIC S AND OR AL 
BIOME TR ANSPL ANT (OBT)
5.1 | Definitions
Microbiome: a community of microorganisms (such as bacteria, fungi 
and viruses) that inhabit a particular environment, and especially 
the collection of microorganisms living in or on the human body 
(Merriam–Webster).	Hence	the	oral	microbiome	is	the	community	of	
microorganisms that inhabit the mouth.
Probiotics: live microorganisms which when administered in ade‐
quate amounts confer a health benefit on the host.42 
Prebiotics: a substrate that is selectively utilized by host microor‐
ganisms, conferring a health benefit.43 
Transplant: to transfer (an organ or tissue) from one part or indi‐
vidual to another (Merriam–Webster Medical Dictionary)
Oral Biome Transplant (OBT): the transfer of live oral microorganisms 
from	one	individual	to	another.	However,	for	a	more	accurate	descrip‐
tion, unless the recipient has their oral cavity rendered gnotobiotic, a 
more appropriate term might be oral biome implant	(OBI)	rather	than	
OBT.	In	this	paper,	the	terms	OBI	and	OBT	are	used	interchangeably.
Dysbiosis: ‘a definitive change in the microbiota at a given site in 
the body, crucially, accompanied by a breakdown of host‐microbial 
mutualism’.44 
5.2 | Oral microbiome
The oral microbiome in health has a symbiotic relationship with the 
host.	Nutrient	supply,	pH,	availability	of	oxygen,	flow	of	salivary	and	
35 Finkelman,	R.	D.,	&	Williams,	R.	C.	(1998).	Local	delivery	of	chemotherapeutic	agents	in	
periodontal	therapy:	Has	its	time	arrived?	J. Clin. Perio., 25, 943–946.
36 Gunsolley,	J.	C.	(2010).	Clinical	efficacy	of	antimicrobial	mouthrinses.	J. Dent., 38	 (S1),	
S6–S10;	Quintas,	V.,	Prada-López,	I.,	Prados-Frutos,	J.	C.,	&	Tomás,	I.	(2015).	In	situ	antimi‐
crobial activity on oral biofilm: Essential oils vs. 0.2 % chlorhexidine. Clin. Oral Invest., 19, 
97–107.
37 Finkelman	&	Williams	op. cit. note 46.
38 Umaki,	T.	M.,	Umaki,	M.	R.,	&	Cobb,	C.	M.	(2012).	The	psychology	of	patient	compliance:	
A focused review of the literature. J. Periodontol., 83, 395–400.
39 Zarco,	 Vess,	 &	 Ginsberg	 op. cit.	 note	 17;	 Tonetti,	 M.	 S.,	 Eickholz,	 P.,	 Loos,	 B.	 G.,	
Papapanou,	P.,	van	der	Velden,	U.,	Armitage,	G.,	...	Suvan	J.	E.	(2015).	Principles	in	preven‐
tion of periodontal diseases. Consensus report of group 1 of the 11th European Workshop 
on	Periodontology	on	effective	prevention	of	periodontal	 and	peri-implant	diseases.	 J. 
Clin. Periodontol., 42	(Suppl.	16),	S5–S11;	Jönsson,	B.,	Öhrn,	K.,	Oscarson,	N.,	&	Linberg,	P.	
(2009). The effectiveness of an individually tailored oral health educational programme on 
oral hygiene behaviour in patients with periodontal disease: A blinded randomized‐con‐
trolled clinical trial (one‐year follow‐up). J. Clin. Periodontol., 36,	1025–1034;	Gao,	X.,	Lo,	E.	
C.	M.,	Kot,	S.	C.	C.,	&	Chan,	K.	C.	W.	(2014).	Motivational	interviewing	in	improving	oral	
health: A systematic review of randomised controlled trials. J. Periodontol., 85, 426–437.
40 Zarco,	Vess,	&	Ginsberg	op. cit.	note	16;	Loozen,	G.,	Boon,	N.,	Pauwels,	M.,	Slomka,	V.,	
Herrero,	E.	R.,	Quirynen,	M.,	&	Teughels,	W.	(2015).	Effect	of	Bdellovibrio	bacteriovorus	
HD100	on	multispecies	oral	communities.	Anaerobe, 35, 45–53.
41 Ibid.;	Marsh,	P.	D.,	Head,	D.	A.,	&	Devine,	D.	A.	 (2015).	Ecological	approaches	to	oral	
biofilms: Control without killing. Caries Res., 49	(Suppl.	1),	46–54.
42 Reid,	G.	(2016).	Probiotics:	Definition,	scope	and	mechanisms	of	action.	Best Practice & 
Research Clin Gastroenterol., 45,	565–568.
43 Gibson,	G.	R.	Hutkins,	R.,	Sanders,	M.	E.,	Prescott,	S.	L.,	Reimer,	R.	A.,	Salminen,	S.	J.,	...	
Reid	 G.	 (2017).	 The	 International	 Scientific	 Association	 for	 Probiotics	 and	 Prebiotics	
(ISAPP)	 consensus	 statement	on	 the	definition	and	 scope	of	prebiotics.	Nature Reviews 
Gastroenterol & Hepatol., 14, 491–502.
44 Mira,	Simon-Soro,	&	Curtis	op. cit. note 13.
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crevicular fluids, and a shedding or non‐shedding surface will allow 
different but stable microbial compositions to become established in 
different oral niches. A contemporary review of the oral microbiome 
concludes: ‘As we increase our understanding of the interplay be‐
tween the environment and the oral microbiome, it will become pos‐
sible to identify new strategies to combat disease by actively 
promoting our natural microbiota and reducing the impact of the 
drivers of dysbiosis.’45 
5.3 | Pro‐ and prebiotics
Pro-	and	prebiotics	work	in	tandem	to	enhance	their	beneficial	ef‐
fect, and there has been a substantial volume of research related to 
the use of probiotics and their effect upon the digestive tract and 
digestive problems. Their mechanism of action remains to be agreed. 
Probiotics	may	swamp	existing	bacterial	colonies,	out-competing	for	
nutrients by vigorous growth, and prebiotics may inhibit the attach‐
ment of pathogenic bacteria and stimulate the immune system. They 
may	have	a	bacteriostatic	or	bactericidal	effect	by	altering	the	pH	of	
the environment.
Confusion	arises	with	the	use	of	probiotic	supplements.	Here	
a small number of specific bacterial species are concentrated and 
then dried to use in powders, capsules or tablets, and sometimes 
even	 lozenges	 and	 gums.	 Nevertheless	 they	 are	 ‘natural’	 and	
hence fall into the category of a legitimate food supplement.46 
5.4 | Oral biome transplant
Nascimento	reported	that	there	was	no	literature	reporting	OBT,	al‐
though he quotes two different hypothetical procedures.47  The first 
involves the collection of plaque from caries‐free individuals and, 
following storage in saline, transfer to the recipient's teeth using a 
nylon swab. The second, more complex, procedure is to treat a pa‐
tient suffering from periodontitis. It involves the collection of supra‐ 
and sub‐gingival plaque from a healthy individual, thorough 
mechanical cleansing of the recipient's teeth, and the application of 
a broad‐spectrum antimicrobial agent immediately followed by its 
neutralization and rinsing with a microbial suspension from the 
healthy donor.
Fecal	microbiota	 transplantation	 (FMT)	 is	an	 instructive	 fore‐
runner	 of	OBT/I.	 It	 is	 gaining	 popularity	 for	 the	management	 of	
Clostridia difficile‐associated diarrhoea,48  where the intention is to 
overwhelm and replace the causative biome with that harvested 
from a ‘healthy’ donor. It has a 90% efficiency of eradicating clos‐
tridium difficile infection (CDI), and would appear to be superior to 
probiotic administration in allowing indigenous gut reconstitution 
following antibiotic therapy.49  Despite a lack of high‐quality trials 
to provide more information on the long‐term safety and risk, 
there has been enthusiastic support for the potential for expand‐
ing	 FMT	 applications,	 including	 to	 gastrointestinal	 disorders	 and	
other diseases, e.g., inflammatory bowel disease, obesity, diabetes 
and even autism.50  The dental community has the opportunity to 
learn	from	the	medical	profession's	experience	of	FMT	and	to	in‐
troduce	OBT/OBI	in	a	safe,	controlled,	targeted	and	effective	man‐
ner.	 The	 rationale	 behind	 OBT/OBI	 is	 to	 introduce	 a	 complete,	
stable community of oral microorganisms to repair or replace the 
dysbiosis.
However,	 the	 transplant	 of	 a	 complete	 human	biome	will	 in‐
clude a spectrum of bacteria, viruses and fungi, and, unless prepa‐
ration of the transplant material screens out harmful organisms, 
both ‘good’ and ‘bad’ microorganisms will be introduced to the 
new host.51 
The problems of a changing biome as the dental plaque ma‐
tures, and the balance with host immunity remain. The immune 
mechanism of the recipient could kill the introduced biome to re‐
gain the status quo, or it could accept the new biome, leading to 
regression of the disease, or the new biome could create a new set 
of unpredictable problems, possibly further along the alimentary 
canal.
If an individual has a healthy mouth, then they must have a 
biome	 that	 is	 symbiotic	with	 them.	Hence,	 given	 the	 variation	 in	
composition of the biome in different areas of the mouth, it needs 
to be determined if a salivary sample will be sufficient, or if a 
plaque sample should be collected. If the latter, a second decision 
regarding the sort of plaque – mature/immature, supra‐/sub‐gingi‐
val	–	needs	to	be	made.	Furthermore,	the	method	and	frequency	
of application of a healthy biome for successful biome modulation 
is unknown. A mouthwash approach will give only a transitory ex‐
posure, which may be insufficient for the colonization of healthy 
bacteria. Inclusion into toothpaste may allow a slightly longer ex‐
posure. The concentration of healthy bacteria in the mouth will 
quickly fall with the normal oral clearance activities, and hence, un‐
less the biome is administered in a highly concentrated form, may 
become ineffective very quickly.
The burgeoning literature suggesting the use of probiotics (+/‐ 
prebiotics) or the transplant of the oral biome as a novel approach in 
the management/prevention of caries and periodontal disease 
45 Marsh	op. cit. note 24.
46  https://www.health.harvard.edu/staying-healthy/the-growing-role-of-probiotics	
Accessed	August	2018
47 Nascimento,	M.	M.	(2017).	Oral	microbiota	transplant;	a	potential	new	therapy	for	oral	
diseases. J Calif Dent Assoc., 45,	565–568.
48 Floch,	 M.	 H.	 (2012).	 The	 power	 of	 poop.	 Probiotics	 and	 fecal	 microbial	 transplant	
(Editorial). J. Clin. Gastroent., 46, 625‐626.
49 Suez,	J.,	Zmora,	N.,	Zilberman-Schapira,	G.,	Mor,	U.,	Dori-Bachash,	M.,	Bashiardes,	S.,	...	
Elinor,	 E.	 (2018).	Post-antibiotic	 gut	mucosal	microbiome	 reconstruction	 is	 impaired	by	
probiotics	and	improved	by	autologous	FMT.	Cell, 174, 1406–1423.
50 Borody,	T.	J.,	&	Campbell,	J.	(2012)	Fecal	microbiota	transplantation:	Techniques,	appli‐
cations, and issues. Gastroentero. Clin. N., 41,	781–803;	Kelly,	C.	R.,	Kahn,	S.,	Kashyap,	P.,	
Laine,	L.,	Rubin,	D.,	Atreja,	A.,	…	Wu,	G.	(2015).	Update	on	fecal	microbiota	transplantation	
2015: Indications, methodologies, mechanisms, and outlook. Gastroenterology, 149, 
223–237.
51 Pozhitkov,	A.	E.,	Leroux,	B.	G.,	Randolph,	T.	W.,	Beikler,	T.,	Flemmig,	T.	F.,	&	Noble,	P.	A.	
(2015). Towards microbiome transplant as a therapy for periodontitis: An exploratory 
study of periodontitis microbial signature contrasted by oral health, caries and edentulism. 
BMC Oral Health, 15, 125–137.
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should be welcomed with caution.52 	Further	research	should	be	sub‐
ject to sound methodology, and results subjected to close scientific 
scrutiny.	Furthermore,	it	is	important	that	the	ethical	aspects	of	the	
use	of	probiotics,	prebiotics	and	OBT/I	for	the	management	of	oral	
diseases should be considered.
6  | ETHIC AL ISSUES A SSOCIATED WITH 
THE USE OF PROBIOTIC S AND/OR BIOME 
TR ANSPL ANTS WITHIN DENTISTRY
The primary use of probiotics in medicine has focused on their com‐
plementary action in the management of intestinal tract problems. 
Probiotics	have	also	been	added	to	commercial	 food	products	be‐
cause of their perceived beneficial effect on human health. It is im‐
portant that the public and professions be adequately prepared for 
making	 informed	 choices	 about	 oral	 probiotics	 and	 OBT/OBI.	
Furthermore,	we	must	appropriately	balance	the	potential	therapeu‐
tic benefits for patients with the current lack of scientific evidence 
and understanding of the risks of oral probiotics. The literature 
shows that the therapeutic use of probiotics is the focus of contem‐
porary	research,	with	OBT/OBI	research	very	much	in	its	infancy.53 
6.1 | Probiotic supplements
With probiotic supplements, the bacteria are concentrated and then 
dried to use in powders, capsules, or tablets, and sometimes even in 
lozenges and gums. The biggest issue with probiotic supplements is 
the lack of oversight. As for other dietary supplements, they do not 
require	Food	and	Drug	Administration	(FDA)	approval,	so	there	is	no	
guarantee that the types of bacteria listed on a label can provide the 
promised	benefits.	Furthermore,	some	products	have	been	found	to	
contain smaller numbers of bacteria than expected, and some may 
contain types not listed on the label. Therefore, it is best to get your 
probiotics from fermented foods.54 
The	option	of	probiotics	and	OBT/OBI	within	dentistry	presents	
many ethical, social and regulatory challenges. There are concerns 
about the long‐term safety and efficacy evaluation of oral probiot‐
ics; about how to determine, select and screen healthy oral biome 
donors to avoid disease transmission; about consent for a minor; 
about commercialization; and about the public health implications. 
In this paper, we will examine the ethical and social issues arising in 
four main areas, with the emphasis on the fourth area:
1. consent;
2. how to determine a suitable healthy oral biome donor;
3. risk and benefit evaluation;
4. commercialization, marketing and regulation.
These ethical and social challenges must be addressed as part of a 
successful regulatory policy response to microbiome‐based treatment 
in dentistry and its effective implementation in practice.
6.2 | Consent
Consent	must	be	voluntary	(without	inducement)	and	informed.	For	
probiotics already in widespread commercial foodstuffs (especially 
yoghurt, usually using a single genus or a small number of different 
bacterial genera), the ethical issues surround product labelling, ad‐
vertisements, regulation, and monitoring of adverse reactions. The 
patient may already be familiar with the word ‘probiotics’ as ingredi‐
ents of their normal food, and believe that they are safe and confer 
positive health benefits. We focus on probiotics specifically targeted 
at the oral flora as a therapeutic measure, because the ethical issues 
here are more complex and are compounded by the vulnerability 
of patients and the uncertainties of safety and risk in oral probiotic 
consumption. Therapeutic use in infants or minors is a particularly 
challenging area, especially when a child is reaching the age when 
parents no longer have legal responsibility. The clinician must be 
assured that the young individual has the capacity to comprehend 
the proposed intervention and is competent to make their own deci‐
sions.	However,	we	believe	that,	 in	both	commercial	and	medicinal	
scenarios, there may be a role for medical professionals in informing 
the patient about the risks and advising on choosing the appropriate 
probiotic products.
To be effectively integrating probiotics in their patients’ care, 
dentists must have an understanding of contemporary evidence re‐
garding oral probiotics and be prepared to inform and discuss probi‐
otics with patients. In common with all other health professionals, 
dentists should practise evidence‐based dentistry; however, the cur‐
rent lack of information regarding the risks/benefits of this approach 
presents a challenge.55  Meanwhile, the patient will be influenced by 
their pre‐existing attitudes and beliefs about probiotic therapies, in‐
cluding inter alia complementary and alternative medicines, pharma‐
cological therapies, and gene‐transfer technologies.56  Each of these 
approaches presents different risk/benefit considerations regarding 
their utility, and patients form their perceptions and expectations 
towards	probiotics	according	to	their	preconceptions.	For	example,	
patients who view probiotics as similar to pharmacological 
52 Meurman,	J.	H.	(2005).	Probiotics:	Do	they	have	a	role	in	oral	medicine	and	dentistry?	
Eur. J. Oral Sci., 113,	188–196;	Bretz,	W.	A.,	&	Rosa,	O.	P.	S.	(2011).	Emerging	technologies	
for the prevention of dental caries. Are current methods of prevention sufficient for the 
high risk patient? Internat. Dent. J., 61	(Suppl.	1)	29–33;	Allaker,	R.	P.,	&	Douglas,	C.	W.	I.	
(2009).	Novel	anti-microbial	therapies	for	dental	plaque-related	diseases.	Int. J. Antimicrob. 
Ag., 33,	8–13;	Goldman,	B.	R.,	&	Goldbach,	S.	L.	(2008).	Clinical	indications	for	probiotics:	
An overview. Clin. Infec. Dis., 46	 (Suppl.	 2),	 S96–100;	 Stomatova,	 I.,	 &	Meurman,	 J.	 H.	
(2009).	Probiotics:	Health	benefits	in	the	mouth.	Am. J. Dent., 22,	329–338;	Cagetti,	M.	G.,	
Mastroberardino,	S.,	Milia,	E.,	Cocco,	F.,	Lingström,	P.,	&	Campus,	G.	 (2013).	The	use	of	
probiotic strains in caries prevention: A systematic review. Nutrients, 5, 2530–2550.
53 Cagetti	et	al.	op. cit. note 62.
54  https://www.health.harvard.edu/staying-healthy/the-growing-role-of-probiotics	
Accessed	Aug,	2018.
55 Bonifait,	L.,	Chandad,	F.,	&	Grenier,	D.	(2009).	Probiotics	for	oral	health:	Myth	or	reality?	
J. Can. Dent. Ass., 75,	585–590;	Seminario-Amez,	M.,	López-López,	J.,	Estrugo-Devesa,	A.,	
Ayuso-Montero,	R.,	&	Jané-Salas,	E.	 (2017).	Probiotics	and	oral	health:	A	systematic	re‐
view. Med. Oral Patol. Oral., 22,	e282–e288.
56 Haukioja,	A.	(2010).	Probiotics	and	oral	health.	Eur. J. Dent., 4,	348–355.
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interventions or dietary supplements may, without professional 
guidance, fail to appreciate the potential risks associated with mi‐
crobe–host interactions resulting from the ingestion of living micro‐
organisms.57  In contrast, if patients regard probiotics as a form of 
complementary and alternative medicine, they may believe that no 
professional guidance is required, considering them as ‘natural’ and 
‘organic’, perceiving them as safer, more effective, and carrying 
fewer health risks. This can lead to an overestimate of their benefits 
and to an underestimate of the risks such as improper use or 
dosage.
Therefore, a dentist's guidance is important in informing the 
patient of the risks and uncertainties of probiotics as a therapeutic 
option, and in avoiding simply categorizing probiotics as a ‘lower‐
risk’ medical modality. Ethical guidance needs to be developed as to 
what constitutes appropriate information for informed consent for 
patients receiving oral probiotics. Clearly this will require those man‐
ufacturing a probiotic to be honest in their listing of ingredients, and 
in reporting any known risks. Continuing independent and rigorous 
scientific assessments of probiotic therapy may yet reveal hitherto 
unsuspected side‐effects/complications or contra‐indications, and 
dental practitioners must stay abreast of contemporary knowledge 
and understanding in this fast‐moving and evolving field.
6.3 | Risk–benefit assessment
Although the use of probiotics is increasing and is considered safe 
overall for healthy people, there are still numerous unanswered clini‐
cal and scientific questions surrounding the oral microbiome and the 
effects of probiotics. This means that balancing possible risks and 
benefits is not easy. The effect of increased and/or prolonged daily 
probiotic consumption in a healthy individual remains unknown.
Introducing a new microbiome might have unanticipated conse‐
quences, especially for certain patient groups, for example those 
with	immune	deficiency,	neonates,	and	young	children.	For	example,	
Lactobacilli	 are	 one	 group	 of	 bacteria	 perceived	 as	 ‘friendly’	 and	
‘beneficial’	 and	 commonly	 used	 in	 probiotic	 products.	However,	 a	
recent case reported a 65‐year‐old diabetic patient who presented 
with a complex liver abscess and a bacteraemia from Lactobacillus 
paracasei owing to probiotic consumption.58  This case, although 
rare, highlights these complications and suggests that our under‐
standing of probiotics as ‘lower risk’ is premature and inadequate.
Sharp	et	al.	identified	four	main	areas	of	non-traditional	safety-
related considerations in the use of probiotics:59 
1. unpredictable behaviour of naturally occurring microorganisms;
2. unpredictable behaviour of genetically altered microorganisms;
3. unexpected interactions of bacteria within the specific local envi‐
ronment of the human host; and
4. unexpected release of novel bacteria into the (external) 
environment.
It is argued that patients who are to make informed choices about 
the use of probiotics must consider the above safety‐related issues, 
which have not been well characterized; otherwise, they may have an 
incomplete appreciation of the risks and cannot make well‐informed 
choices about probiotic therapies.
Some	studies	raise	concerns	about	the	use	of	probiotics	in	young	
children. Changes of the gut microbiome at a young age might have 
a long‐term impact on health because the early‐life frame is critical 
– the immune system is still developing and is in part shaped by the 
gut microbiota.60  Although most research is focused on the use of 
antibiotics,61  given the significance of microbiota modulation for 
young children, doctors should be informed by increasing knowl‐
edge associated with human microbiome research before patients 
are	advised	to	use	probiotics.	Larger,	longer	and	better	studies	are	
needed to test specific strains for specific conditions and to deter‐
mine the proper doses and regimens.
It is also prudent to consider whether there are any safety con‐
cerns associated with the resulting increased exposure to live mi‐
crobes. It is important to note that the question of safety is not only 
about the probiotic strain being used, but also about how the strain 
is	used	and	who	is	consuming	it.	For	example,	a	safety	assessment	
for a strain administered intravaginally would be different from one 
for	the	same	strain	administered	orally.	Similarly,	an	assessment	for	
a strain used in yoghurt at 109	colony	forming	units	 (CFU)/serving	
would be different from one for the same strain administered at 
1012	CFU/enteric-coated	capsules.62  The profession is also at the 
mercy of the food and pharmaceutical industry. Major brands when 
tested, however, mostly correctly reported content and 
concentration.63 
It is apparent that there is a publication bias in favour of probiot‐
ics,64  with just over a third of trials giving no information on harm.65  
Goldacre	has	repeatedly	taken	the	pharmaceutical	industry	to	task	
over their wilful avoidance of full disclosure of the results of clinical 
trials.66  Unrefereed monographs in favour of probiotics are easily 
57 Sharp,	R.	R.,	Achkar,	J.-P.,	Brinich,	M.	A.,	&	Farrell,	R.	M.	(2009).	Helping	patients	make	
informed choices about probiotics: a need for research. Am. J. Gastroenterol., 104,	809–
813;	Snydman,	D.	R.	(2008).	The	safety	of	probiotics.	Clinical Infectious Diseases, 46	(Suppl.	2),	
S104–S111;	discussion	S144–S151.
58 Pararajasingam,	A.,	&	Uwagwu,	J.	(2017).	Lactobacillus:	The	not	so	friendly	bacteria.	Brit. 
Med. J. Case Reports.	https://doi.org/10.1136/bcr-2016-218423
59 Sharp	et	al.	op. cit.	note	81.
60 Schulfer,	A.,	&	Blaser,	M.	J.	(2015).	Risks	of	antibiotic	exposures	early	in	life	on	the	devel‐
oping microbiome. PLoS Pathog., 11, e1004903.
61 Zeissig,	S.,	&	Blumberg,	R.	S.	(2014).	Life	at	the	beginning:	Perturbation	of	the	microbiota	
by antibiotics in early life and its role in health and disease. Nat. Immunol., 15, 307–310.
62 Sanders,	M.	E.,	Gibson,	G.	R.,	Gill,	H.	S.,	&	Guarner,	F.	(2007).	Probiotics:	Their	potential	
to impact human health. Council for Agricultural Science and Technology Issue Paper, 36, 
1–20.
63 https:/cspinet.org/tip/should-you-take-probiotic-every-day.	Accessed	Sept,	2018.
64 Million,	M.,	&	Raoult,	D.	 (2012).	Publication	biases	 in	probiotics.	Eur. J. Epidemiol., 27, 
885–886.
65 Mayor,	S.	(2018).	Sixty	seconds	on	…	probiotics.	Nrit. Med. J., 362,	17th	July.	https://doi.
org/10.1136/bmj.k3134;	Bafeta,	A.,	Koh,	M.,	Riveras,	C.,	&	Ravoud,	P.	(2018).	Harms	re‐
porting in randomised controlled trials of interventions aimed at modifying microbiota. A 
systematic review. Ann. Int. Med., 169, 240–247.
66 Goldacre,	 B.	 (2008).	 Bad Science.	 London,	 UK:	 4th	 Estate;	 Goldacre,	 B.	 (2013).	 Bad 
Pharma.	London,	UK:	4th Estate
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found on the internet. Their commercial sponsorship can sometimes 
be difficult to identify, and they may mislead the public.
7  | OBT/I :  HOW TO DETERMINE A 
SUITABLE HE ALTHY OR AL BIOME DONOR
For	 fecal	 microbiota	 transplantation	 (FMT),	 working	 out	 how	 to	
define, identify and source optimal donors has become a pressing 
clinical demand and a research area worthy of multidisciplinary in‐
vestigation.	OBT/I	raises	similar	questions,	and	it	poses	both	medical	
and ethical challenges.
Screening	 for	potential	OBT/I	donors	 shares	a	number	of	con‐
cerns	with	those	previously	expressed	in	relation	to	FMT,67  and Ma 
et al. distinguished between the ‘ideal (or optimal)’ donor and the 
‘healthy’ donor.68 	Our	ignorance	of	what	might	constitute	an	‘opti‐
mal’ oral biome, how to screen potential donors, and what standards 
should be applied to screen the donors means that we are unable to 
identify which healthy individuals might be donors for patients with 
identified oral disease. It should be noted that while we believe that 
the diversity of bacteria associated with periodontal disease is very 
high,69  we know that the diversity of bacteria for CDI is very low;70  
thus,	we	should	not	follow	the	FMT	standards	to	choose	donors	for	
OBT/I.
The association between dysbiosis in the oral microbiome and 
systemic disease means that caution and prudence are required in 
modulating the oral biome, as modulation may have a profound and 
unintended impact on systemic health and overall well‐being, and 
many	of	the	effects	are	still	unknown.	For	example,	we	know	that	
diabetes is a risk factor for periodontitis, causing a shift in oral bac‐
terial composition and making it more pathogenic.71 
The link between oral pathogens and systemic effects has been 
evidenced by a recent study in animals, which suggests that peri‐
odontitis	is	a	risk	factor	for	various	systematic	diseases.	For	exam‐
ple, repeated oral administration of Porphyromonas gingivalis elicited 
endotoxemia via changes in the gut microbiota of the ileum, and in‐
duced systemic inflammation and insulin resistance,72  and oral 
Klebsiella spp. can colonize the dysbiotic gut microbiota in a suscep‐
tible host, leading to an exacerbation of intestinal disease.73  As 
noted above, oral bacteria have been implicated in a number of sys‐
temic diseases, including cardiovascular disease, rheumatoid arthri‐
tis, adverse pregnancy outcomes, stroke, inflammatory bowel 
disease and colorectal cancer, respiratory tract infection, diabetes, 
and possibly dementia.74 
These potential impacts extend beyond the traditional percep‐
tion of ‘healthy’ and ‘risk’, and these terms warrant attention and fur‐
ther research. Apart from traditional oral health standards, the links 
to a variety of systemic conditions mandate that we should examine 
the overall health of the oral biome donor and perhaps the donor's 
genetic susceptibility to certain diseases. Apart from the careful 
screening standards and donor commitment requirements, there are 
various other uncertainties associated with the donor profile.
For	example,	it	is	unclear	at	what	age	transplant	might	be	consid‐
ered for both donor and recipient, and whether there should there 
be age limits set for donors. Caries is a disease of childhood and early 
adolescence – hence we should consider if a transplant should be 
considered	as	the	dentition	erupts,	i.e.,	at	about	6	months	old.	Our	
understanding of the changes in the oral biome as a child grows and 
develops	 is	poor.	Forecasting	 the	development	of	 the	elements	of	
the biome responsible for dental caries in a young child cannot yet 
be	made.	Parental	responsibility	for	consent	for	a	minor	either	as	a	
donor	 or	 as	 a	 recipient	 adds	 a	 further	 complication.	 Furthermore,	
there may be a concern regarding harvesting the oral biome from 
an adult for transplant into a young child's mouth when the child's 
immune system has yet to fully mature. In addition, the religious 
background of donor and/or recipient, particularly where this entails 
special dietary requirements, should be considered when allocating 
oral	microbiota	 to	recipients.	Gender	should	be	also	considered	 in	
allocating transplant.
It is also important to provide both the donor and the recipient 
with information about the procedures they will undergo, including 
screening, the time commitment involved, and their right to decline, 
before they enter into agreement. There are also important issues 
related to privacy, protection and confidentiality.
8  | COMMERCIALIZ ATION, MARKETING 
AND REGUL ATION
Probiotics	are	available	commercially	in	many	products,	but	primar‐
ily as foods and/or dietary supplements. Yoghurt is perhaps the most 
common probiotic‐carrying food, but the market has expanded 
67 Kazerouni,	A.,	Burgess,	J.,	Burns,	L.	J.,	&	Wein,	L.	M	Optimal	screening	and	donor	man‐
agement in a public stool bank. Microbiome. 2015. 3:75
68 Ma,	Y.,	Liu,	J.,	Rhodes,	C.,	Nie,	Y.,	&	Zhang,	F.	(2017).	Ethical	issues	in	fecal	microbiota	
transplantation in practice. Am. J. Bioethics, 17(5), 34–45.
69 Paster,	B.	J.,	Olsen,	I.,	Aas,	J.	A.,	&	Dewhirst,	F.	E.	(2006).	The	breadth	of	bacterial	diver‐
sity in the human periodontal pocket and other oral sites. Periodontology 2000., 42, 
80–87.
70 Song,	Y.,	Garg,	S.,	Girotra,	M.,	Maddox,	C.,	von	Rosenvinge,	E.	C.,	Dutta,	A.,	…	Fricke,	W.	
F.	(2013).	Microbiota	dynamics	in	patients	treated	with	fecal	microbiota	transplantation	
for recurrent Clostridium difficile infection. PloS One, 8,	e81330.
71 D'Aiuto,	F.,	Gable,	D.,	Syed,	Z.,	Allen,	Y.,	Wanyonyi,	K.	L.,	White,	S.,	&	Gallagher,	 J.	E.	
(2017). Evidence summary: The relationship between oral diseases and diabetes. Brit. 
Dent. J., 222,	944–948;	Xiao,	E.,	Mattos,	M.,	Vieira,	G.	H.	A.,	Chen,	S.,	Correa,	J.	D.,	Wu,	Y.,	
…	Graves,	D.	T.	(2017).	Diabetes	enhances	IL-17	expression	and	alters	the	oral	microbiome	
to increase its pathogenicity. Cell Host Microbe, 22,	120–128.
72 Nakajima,	 M.,	 Arimatsu,	 K.,	 Kato,	 T.,	 Matsuda,	 Y.,	 Minagawa,	 T.,	 Takahashi,	 N.,	 …	
Yamazaki,	K.	(2015).	Oral	administration	of	P. gingivalis induces dysbiosis of gut microbiota 
and impaired barrier function leading to dissemination of enterobacteria to the liver. PloS 
One, 10, e0134234.
73 Atarashi,	K.,	 Suda,	W.,	 Luo,	C.,	Kawaguchi,	 T.,	Motoo,	 I.,	Narushima,	 S.,	 ...	Honda,	H.	
(2017).	Ectopic	colonization	of	oral	bacteria	in	the	intestine	drives	TH1	cell	induction	and	
inflammation. Science, 358(6361), 359–365.
74 Dietrich,	T.,	Webb,	I.,	Stenhouse,	L.,	Pattni,	A.,	Ready,	D.,	Wanyonyi,	K.	L.,	…	Gallagher,	J.	
E. (2017). Evidence summary: The relationship between oral and cardiovascular disease. 
Brit. Dent. J., 222,	381–385;	Manger,	D.,	Walshaw,	M.,	Fitzgerald,	R.,	Doughty,	J.,	Wanyonyi,	
K.	L.,	White,	S.,	&	Gallagher,	J.	E.	(2017).	Evidence	summary:	The	relationship	between	oral	
health and pulmonary disease. Brit. Dent. J. 222, 527–533.
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beyond yoghurt. Cheese, fermented and unfermented milk, juices, 
smoothies, cereals, nutrition bars, and infant formula are all foods 
used	 by	 the	 probiotic	 industry.	 Probiotics	 are	 also	 sold	 as	 dietary	
supplements, medical foods, and drugs in the form of capsules, tab‐
lets,	or	 sachets.	Probiotics	are	a	big	and	 rapidly	growing	business,	
with	annual	global	sales	of	products	reaching	$36.6	billion	US	dollars	
in 2015, and expected to exceed $64 billion dollars by 2023.75  This 
industry is built on the belief that certain types of bacteria offer 
health benefits, although scientific evidence is still inadequate. 
Moreover,	 the	 increase	 in	 the	 geriatric	 population	 in	 the	U.S.	 and	
Europe suffering from obesity and associated digestive disorders, as 
well as increasing consumer preference for natural products coupled 
with a growing concern for preventive healthcare, will drive product 
demand.	Owing	to	the	hectic	lifestyle	of	the	working	population,	ris‐
ing	 consumer	 awareness	 in	 Japan	 and	 China	 towards	 functional	
foods is driving the growth of the probiotic industry. Ethical issues 
arise from the production and distribution of probiotic products 
promising maintenance or restoration of good health and disease 
prevention without robust evidence to support each specific claim.
There is scientific evidence that specific strains of probiotic mi‐
croorganisms confer health benefits on the host and are safe for 
human	use.	However,	this	evidence	cannot	be	extrapolated	to	other	
strains, as these effects are strain‐specific.76  This approach could 
open the door to the commercialization of the scientific value of 
‘good’ bacteria, and some pharmaceutical companies may cite the 
findings and claim health benefits even though their commercial 
products may not have the same strains and formulations as those 
tested in published studies. Moreover, studies suggest that these 
claims have the potential to appear in the widespread commercial‐
ization of a range of over‐the‐counter probiotics,77  for example the 
push for probiotic anything, such as probiotic body lotion, probiotic 
chewing gum for oral health, and even probiotic shampoo for curing 
dandruff. There are serious ethical concerns over these unsubstanti‐
ated health claims and safety issues, especially for products that em‐
phasize natural ingredients while minimizing the synthetic or 
bioengineered	 ingredients.	 Furthermore,	 people	may	 be	 attracted	
by the convenience, ready access and easy consumption of probiot‐
ics; for example, brushing and flossing takes time and effort, but tak‐
ing oral probiotics, as in, for instance, a small drink that claims to 
deliver improvements in oral health, seems simple and easy.
In a health‐oriented consumer culture, the commercialization of 
health	products	 is	very	powerful.	Scientific	debate	over	the	effec‐
tiveness and safety of food supplements and probiotics does not 
affect	their	popularity.	Nettleton	refers	to	this	culture	as	a	new	par‐
adigm of health, which ‘emphasises individual responsibility and 
lifestyle changes for ensuring good health and preventing disease’.78  
As	Slashinski	et	al.	further	point	out,	in	this	culture,	‘marketing	strat‐
egies adopt this rhetoric of individual responsibility, constructing the 
body in a state of imbalance, providing consumers with a choice to 
be healthy, and then encouraging them to be proactive’.79  In coun‐
tries where advertising is permitted by law, it must not create unnec‐
essary treatment needs, promise unrealistic results, or be misleading, 
unfair or disrespectful towards the healthcare professionals and col‐
leagues;	 for	 example,	 the	 United	 Kingdom	 Advertising	 Standards	
Agency has extensive guidance for advertising food supplements.80 
8.1 | Regulation
From	a	legal	point	of	view,	the	intended	use	of	a	probiotic	will	deter‐
mine its regulation. If it is used as a therapeutic intervention, then it 
must	be	approved	by	the	FDA	in	the	U.S.A.	If	it	is	a	dietary	supple‐
ment	or	additive,	the	FDA	should	be	informed,	but	approval	 is	not	
necessary because, within certain constraints,81  the ingredient will 
be	 considered	 ‘generally	 recognized	 as	 safe’	 (GRAS).	 Concern	 re‐
garding the presence of potentially harmful contaminants has led the 
FDA	to	improve	its	methodology	for	assessing	the	purity	of	probiotic	
products.82  If it is a food supplement, there is no universal regula‐
tory framework. The spectrum of regulation from belief that the 
public needs protection from the unsubstantiated claims of the pro‐
ducer/manufacturer (the European Union) to an assumption that an 
informed and sophisticated consumer is protected by honest pro‐
ducers/manufacturers	(U.S.A.).83 	There	is	evidence	that	in	the	U.S.A.	
the approach is changing.84 	 A	 regulation	 by	 the	 European	 Food	
Safety	Authority	(EFSA)	that	makes	it	hard	to	demonstrate	the	ben‐
efits of probiotics is the prohibition of medical claims, i.e., claims that 
a food prevents or cures a disease unless supported by research.85 
A	considered	debate	is	yet	to	be	held	regarding	the	use	of	OBT/I	
in the management of oral disease. As noted above, the oral cavity 
harbours approximately 700 different bacteria, and together with 
other microbes presents a complex ecosystem. It is also understood 
75 Global	Market	Insights.	Available	from	https://www.gminsights.com/industry-analysis/
probiotics-market	(Accessed	Oct,	2018)
76 Senok,	A.	C.,	 Ismaeel,	A.	Y.,	&	Botta,	G.	A.	 (2005).	 Probiotics:	 Facts	 and	myths.	Clin. 
Microbiol. Infec., 11,	958–966.
77 Slashinski,	M.	 J.,	McCurdy,	 S.	A.,	Achenbaum,	 L.	 S.,	Whitney,	 S.	N.,	&	McGuire,	A.	 L.	
(2012).	 ‘Snake-oil,’	 ‘quack	medicine,’	 and	 ‘industrially	 cultured	organisms:’	Biovalue	 and	
the commercialization of human microbiome research. BMC Medical Ethics, 13,	28–35.
78 Nettleton,	S.	(2013).	The sociology of health and illness	(3rd	ed.).	Malden:	Polity.
79 Slashinski	et	al.	op. cit. note 109.
80 Advertising	Standards	Agency.	Food,	food	supplements	and	associated	health	or	nutri‐
tion claims. https://www.asa.org.uk/type/broadcast/code_section/13.html (Accessed 
Oct,	2018).
81 Mattia,	 A.,	 &	Merker,	 R.	 (2008).	 Regulation	 of	 probiotic	 substances	 as	 ingredients	 in	
foods:	 Premarket	 approval	 of	 ‘generally	 recognised	 as	 safe’	 notification.	 Regulation	 of	
Probiotics	as	Ingredients.	CID,	46	(Suppl.	2),	S115–S118.
82 FDA	developing	 improved	methodology	for	determining	purity	of	probiotic	products.	
https://www.fda.gov/biologicsbloodvaccines/scienceresearch/ucm493
83 Hoffman,	D.	E.,	Fraser,	C.	M.,	Palumbo,	F.	B.,	Ravel,	J.,	Rothemberg,	K.,	Rowthorn,	V.,	&	
Schwartz,	 J.	 (2013).	Probiotics:	Finding	 the	right	 regulatory	balance.	Science, 342, 314–
315;	Hoffman,	D.	E.	(2013).	Health	claim	regulation	of	probiotics	in	the	USA	and	the	EU:	is	
there a middle way? https://digitalcommons.law.umaryland.edu/fac_pubs/1334/. 
Accessed	Sept,	2018.
84 Dreher-Lesnick,	S.,	Stibitz,	S.,	&	Carlson,	P.,	Jr	(2017).	U.S.	Regulatory	Considerations	for	
Development	of	Live	Biotherapeutic	Products	as	Drugs.	Microbiol. Spectrum https://doi.
org/10.1128/microbiolspec.bad-0017-2017
85 Katan,	M.	B.	(2012).	Why	the	European	Food	Safety	Authority	was	right	to	reject	health	
claims for probiotics. Benefic. Microb., 3,	85–89;	Binnendijk,	K.	H,	&	Rijkers,	G.	T.	(2013).	
What	is	a	health	benefit?	An	evaluation	of	EFSA	opinions	on	health	benefits	with	refer‐
ence to probiotics. Benefic. Microb. https://doi.org/10.3920/bm2013.0019
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that both caries and periodontal disease do not have a monospecies 
aetiology.	If	OBT/I	and	or	probiotics	are	to	be	used	to	restore	a	har‐
monious oral ecosystem, then it is likely that polymicrobial therapy 
will be required and used as a therapeutic measure. Can this ap‐
proach be considered under the heading of an ‘additive’ or ‘supple‐
ment’ and subject to the same regulation as that of food or drink 
already marketed as ‘probiotic’ or should it be subject to more strin‐
gent regulation as a true therapeutic agent? Can we expect the food 
and drink industry to behave in a responsible manner, given their 
reluctance to reduce sugar consumption in the face of overwhelming 
evidence of the harm caused to health?86 
To effectively regulate the world of probiotic products, probiotic 
researcher	Dr	Gregor	Reid	proposed	a	 framework	 for	 categorizing	
microorganisms in consumer and clinical products (including food 
and drugs) into levels depending on the degree of safety, efficacy, 
and characterization of the microorganism.87  According to the 
‘Working	 Group’	 in	 the	 National	 Institutes	 of	 Health	 Human	
Microbiome	Project,	although	no	consensus	was	reached	among	reg‐
ulators, it was agreed that the concept provided a useful framework 
for assessing/categorizing probiotic products and thinking about 
how they should be regulated depending on what scientific evidence 
is available about a specific strain or product. It is also noted that this 
might be useful in determining when an investigational new drug ap‐
plication is required, and what claim can be made about a product.
9  | CONCLUSIONS
Our	understanding	of	the	complexity	of	the	oral	biome	and	of	the	
role of the various constituent bacteria in the aetiology of dental 
disease	 is	growing.	Probiotics	and	OBT/I,	as	well	as	other	microbi‐
ome‐based interventions, could be useful in preventing and treat‐
ing	dental	disease	and	in	promoting	oral	health.	However,	given	the	
early stage of this treatment approach, we cannot speculate on the 
success or failure of bacteriotherapy for oral diseases. There are also 
a number of ethical, social, and regulatory issues associated with in‐
novative probiotic therapy. In this article, we focused primarily on 
four core issues: informed consent, risk–benefit assessment, how to 
determine suitable healthy donors, and commercialization and regu‐
lation. We discussed the safety and benefits of oral probiotics, not 
only concerning the products and their quality control during manu‐
facturing, but also the depth of public knowledge about this topic. 
We pointed out that the requirement of listing ingredients honestly 
might be insufficient; furthermore prevalent rhetoric of ‘natural’ and 
‘organic’ as well as some health claims in the translational, innova‐
tive probiotic industry and markets are themselves misleading and 
should also be carefully scrutinized.
With the development of human microbiome research, our en‐
thusiasm for modulating the human microbiome to affect health 
will increase, and will be accompanied by the increasing availabil‐
ity of over‐the‐counter oral probiotics and dietary supplements. 
Manufacturers are responsible for ensuring the safety of their 
products and for being truthful about the actual health benefits. 
Probotics	 should	 be	 used	 with	 caution	 in	 vulnerable	 persons.	 To	
meet the growing health needs of patients and users in the popula‐
tion, more research is required to examine whether the current reg‐
ulatory framework is a good fit for the range of probiotics that are 
on the market, still under development, and may be developed in the 
future. It is an ethical imperative to find a balance between scientific 
research, market and industry, and public health in the regulation of 
probiotics.
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